Cytosorbents Corp CTSO

NAS: CTSO | ISIN: US23283X2062   30/04/2025
1,010 USD (-9,82%)
(-9,82%)   30/04/2025

29 april 2025 · CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights · Persbericht

21 april 2025 · CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program · Persbericht

17 april 2025 · CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller · Persbericht

14 april 2025 · CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America · Persbericht

4 april 2025 · CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants · Persbericht

31 maart 2025 · CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights · Persbericht

21 maart 2025 · CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit · Persbericht

30 juli 2024 · CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website · Persbericht

14 augustus 2023 · CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial · Persbericht

27 februari 2023 · CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference · Persbericht

24 februari 2023 · CytoSorbents to Report Fiscal 2022 Operating and Financial Results · Persbericht

31 januari 2023 · CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue · Persbericht

23 januari 2023 · CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial · Persbericht

17 januari 2023 · CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs · Persbericht

29 december 2022 · CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement · Persbericht

21 december 2022 · CytoSorbents Receives Recommendation from Independent Data and Safety Monitoring Board to Continue Pivotal STAR-T Trial As Planned Without Modifications · Persbericht

14 november 2022 · CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled · Persbericht

3 november 2022 · CytoSorbents Reports Third Quarter 2022 Financial and Operational Results · Persbericht

2 november 2022 · 'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals · Persbericht

31 oktober 2022 · National Institutes of Health Grants Phase I SBIR Award to CytoSorbents to Test Novel Polymers for Cytokine and Endotoxin Removal from Septic Porcine Plasma · Persbericht

Mijn selecties